The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

Schittenhelm, Marcus M.; Kampa-Schittenhelm, Kerstin Maria; Yee, Kevin W. H.; Heinrich, Michael C.

dc.contributor.author	Schittenhelm, Marcus Matthias
dc.contributor.author	Kampa-Schittenhelm, Kerstin Maria
dc.date.accessioned	2015-04-02T12:30:12Z
dc.date.available	2015-04-02T12:30:12Z
dc.date.issued	2009
dc.identifier.issn	1538-4101
dc.identifier.issn	1551-4005
dc.identifier.uri	http://hdl.handle.net/10900/62527
dc.language.iso	en	de_DE
dc.publisher	Abingdon : Tayler & Francis	de_DE
dc.relation.uri	http://dx.doi.org/10.4161/cc.8.16.9355	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin	de_DE
dc.type	Article	de_DE
utue.publikation.seiten	2621-2630	de_DE
utue.personen.roh	Schittenhelm, Marcus M.
utue.personen.roh	Kampa-Schittenhelm, Kerstin Maria
utue.personen.roh	Yee, Kevin W. H.
utue.personen.roh	Heinrich, Michael C.
dcterms.isPartOf.ZSTitelID	Cell Cycle	de_DE
dcterms.isPartOf.ZS-Issue	16	de_DE
dcterms.isPartOf.ZS-Volume	8	de_DE